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categorized using the Clavien-Dindo classification reporting 
system. The mean follow-up was 21 months.  Results: The 
median hospital stay was 17 (2–91) days. Perioperative Cla-
vien-Dindo grade  ≥ III complications were seen in 24.1% 
(48/199) of group 1 patients and 19.2% (10/52) of group 2 
patients (p = 0.045). 30- and 90-day mortality was 4.5 and 
13.5% in group 1 and 6.5 and 32.3% in group 2, respectively. 
Only the 90-day mortality rate was statistically significant 
(p < 0.05) between the two groups. The 3-year overall sur-
vival was 40% in group 1 and 34% in group 2. The 3-year 
cancer-specific survival was 52% in group 1 and 50% in 
group 2.  Conclusions: We evaluated a large series of elderly 
( ≥ 75 years) patients undergoing radical cystectomy at four 
institutions. Comparing patients aged  ≥ 75–84 and  ≥ 85 
years revealed no significant difference in complications,
30-day mortality, overall and cancer-specific survival rates. 
Only 90-day mortality rates were significantly higher in the 
 ≥ 85-year-old patients.  © 2014 S. Karger AG, Basel 
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 Abstract 
 Introduction: The purpose of this study was to evaluate and 
compare complications after radical cystectomy in patients 
aged  ≥ 75 years.  Materials and Methods: 251 patients aged 
75–95 years (median 79) underwent radical cystectomy be-
tween 2000 and 2012 at four institutions. The patients were 
divided into two groups:  ≥ 75–84 years of age (group 1) ver-
sus  ≥ 85 years of age (group 2). Comorbidities, body mass 
index, and complications were obtained retrospectively, ex-
cept at the Central Hospital of Bolzano and Weill Cornell 
Medical Center, which collected data prospectively. Cancer-
specific survival, overall mortality, hospital stay, clinical out-
come and complications were assessed. Complications were 
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 Bladder cancer (BC) is a disease of the elderly with a 
peak incidence at 85 years  [1] . Over the last five decades, 
demographic changes have taken place in Western coun-
tries resulting in an aging population. As life expectancy 
increases, it is estimated that in 20 years nearly half of the 
population will be considered elderly and that by 2030, the 
number of octogenarians will be 3-fold higher than today 
 [2] . As the peak incidence of BC is not reached until 85 
years of age, the incidence of BC, including muscle-inva-
sive BC, will increase with this aging population  [3–6] .
 Currently, radical cystectomy (RC) remains the gold 
standard for the treatment of muscle-invasive BC  [7] . Im-
provements in surgical and pre- and postoperative care 
have occurred making RC a safer procedure even in el-
derly patients  [8] , it is however often avoided due to 
 concerns about higher morbidity and mortality rates  [3] . 
Hollenbeck et al.  [9] reported that aggressive surgical 
management of BC in elderly patients may improve sur-
vival, but the optimal management of elderly patients 
with muscle-invasive BC is controversial  [10–12] .
 RC is not a surgical intervention without risks. Large 
contemporary series with an average age of approximate-
ly 63 years show complication rates of 24–61% and 90-
day mortality rates of approximately 10–37%  [1, 13] . Due 
to increased comorbidities, decreased physiological re-
serve and decreased ability to respond to stressors, elder-
ly patients have an increased risk of complications  [14, 
15] . This risk must be weighed against the risk of cancer 
recurrence and progression. Unfortunately, if left un-
treated, only 14% of patients with muscle-invasive BC 
will survive beyond 2 years  [1] .
 Patients  ≥ 65 years are considered elderly. Elderly pa-
tients are often subdivided into three categories: young-
old (65–74 years of age), old-old ( ≥ 75–84 years of age) and 
oldest-old ( ≥ 85 years of age)  [16, 17] . We hypothesized 
that the oldest-old RC patients have a higher rate of com-
plications compared to the old-old. To test this hypothe-
sis, we analyzed patients  ≥ 75 years who were treated with 
RC at four separate institutions for invasive BC; group 1 
included patients aged  ≥ 75–84 years (old-old) and group 
2 included patients aged  ≥ 85 years (oldest-old).
 Materials and Methods 
 All four submitting institutions obtained institutional review 
board approval. Out of 536 ( ≥ 75 years) patients only a complete 
follow-up was available for 251, which was the cohort that under-
went RC with removal of regional lymph nodes between 2000 and 
2012. The follow-up schedule was conducted in all four institu-
tions in accordance with the EAU guidelines for BC  [18] .
 The Central Hospital of Bolzano and Weill Cornell Medical 
Center collected their data prospectively, while the Huntsman 
Cancer Institute at the University of Utah and the Ludwig Maxi-
milians University collected their data retrospectively. The pa-
tients were subdivided into two groups: group 1 old-old ( ≥ 75–84 
years of age; mean and median 78 years; n = 199, 79.3%) and group 
2 oldest-old ( ≥ 85 years of age; range 85–94 years; mean and me-
dian 87 years; n = 52 patients, 20.3%).
 The following clinical parameters were evaluated in this study: 
age, body mass index (BMI), comorbidities, the American Society 
of Anesthesiologists (ASA) score, ECOG score and complications. 
All complications occurring within 1 year of surgery were record-
ed, defined and graded according the Clavien-Dindo classification 
(CDC) system  [19] . Complications were divided into early (0–30 
days after RC), delayed (31–90 days after RC) and late complica-
tions (91–365 days after RC).
 A χ 2 was performed to assess differences between categorical 
variables and the Mann-Whitney U test for continuous variables. 
Overall survival and cancer-specific survival were plotted using the 
Kaplan-Meier methodology. A log-rank test was employed to as-
sess the impact of categorical variables on survival. Multivariate 
logistic regression models to evaluate the impact of possible risk 
factors (age >75, chronic obstructive pulmonary disease (COPD), 
BMI, prior abdominal surgery, peripheral vascular disease, hyper-
tension, diabetes mellitus, ASA score >2, ECOG score >1 and kind 
of urinary diversion) on 30- and 90-day mortality and CDC III–IV 
were performed.
 A p value of <0.05 was considered statistically significant. All 
statistical analyses were performed with the SPSS software version 
17.0.1 (SPSS, Inc., Chicago, Ill., USA). All tests are two-sided.
 Results 
 Patient Characteristics 
 Table 1 shows the characteristics of both groups. There 
were 46 females and 205 males with a mean age of 80.7 
years (median 79). Overall, 240 patients underwent RC 
and 11 underwent partial cystectomy with dissection of 
the regional lymph nodes (range 2–43 lymph nodes, me-
dian 11). Median follow-up for the entire cohort was 12 
months (range 1–127, mean 21). 34% of group 1 and 58% 
of group 2 had an ASA score  ≥ 3 (p = 0.002). There were 
no statistically significant differences between the groups 
with regard to prior abdominal surgery, COPD, abdomi-
nal aortic aneurysm, hypertension, diabetes or ECOG 
scores. Of 251 patients, 2 received a neoadjuvant and 1 an 
adjuvant chemotherapy; the rest of the patients (248/251; 
98.8%) had no adjuvant or neoadjuvant chemotherapy.
 Therapeutic Interventions 
 Urinary diversions performed were as follows: ileum 
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bladder in 10, and colon conduit in 40 patients. Urinary 
diversions/surgical approach in the two groups were as 
follows: for group 1: ileum conduit in 108 (54.27%), ure-
tero-ureterocutaneostomy in 35 (17.59%), neobladder in 
10 (5.03%), colon conduit in 37 (18.59%), and partial cys-
tectomy in 9 (4.52%) patients, and for group 2: ileum 
 conduit in 36 (69.23%), uretero-ureterocutaneostomy in 
11 (21.15%), neobladder in 0 (0%), colon conduit in 3 
(5.77%), and partial cystectomy in 2 (3.85%) patients.
 Hospital Stay and Mortality Rates 
 Median length of hospital stay was 18 days in group 1 
and 17 days in group 2. 30- and 90-day mortality of the 
entire cohort was 4.9% (7/142) and 17.6% (25/142), re-
spectively.
 In group 1, 118/199 patients (59.3%) died during fol-
low-up (range 1–127 months) of which 62.7% (74/118) 
died from BC progression. 30- and 90-day mortality in 
group 1 was 4.5% (5/111) and 13.5% (15/111), respec-
 Table 1.  Patient characteristics
Entire cohort Group 1 Group 2 p value
Patients, n 251 199 52
Age at RC, years, median (range) 79 (75 – 95) 79 (75 – 84) 87 (85 – 95)
Male gender, n (%) 205 (81.7) 162 (81.4) 43 (82.7) 0.831
BMI, median (range) 24.6 (15.2 – 40.89) 25 (16.7 – 40.89) 23.3 (15.2 – 34.54)
COPD, n (%) 43 (17.1) 35 (17.6) 8 (15.4) 0.707
Abdominal aortic aneurysm, n (%) 17 (6.7) 13 (6.5) 4 (7.7) 0.767
Prior abdominal surgery, n (%) 60 (24) 44 (22) 16 (31.8) 0.192
Peripheral vascular disease, n (%) 31 (12.3) 24 (12.1) 7 (13.5) 0.785
Diabetes mellitus, n (%) 43 (17) 36 (18) 7 (13.4) 0.430
Hypertension, n (%) 114 (45.4) 91 (45.7) 23 (44.2) 0.847
ASA score >2, n (%) 67 (33.7) 30 (57.7) 0.002


























Cis present, n 90 72 18
 Table 2.  Clinical characteristics
Entire cohort Group 1 Group 2 p value
Cumulative hospital stay, median (range) 17 (2 – 91) 18 (2 – 91) 17 (4 – 51) 0.194
30-day mortality, n (%) 7/142 (4.9) 5/111 (4.5) 2/31 (6.5) 0.658
90-day mortality, n (%) 25/142 (17.6) 15/111 (13.5) 10/31 (32.3) 0.015
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tively. In group 2, 31/52 patients (59.6%) died during 
follow-up of which 54.8% (17/31) died of BC progres-
sion. 30- and 90-day mortality in group 2 was 6.5% 
(2/31) and 32.3% (10/31), respectively. In multivariate 
logistic regression none of the clinical parameters as-
sessed at the time of diagnosis influenced significantly 
30-day mortality, while the presence of COPD and an 
age of >84 years were significant prognosticators for 90-
day mortality.
 The estimated 3-year overall survival rate was 40% in 
group 1 and 34% in group 2 (p = 0.097). The estimated 
3-year cancer-specific survival rate was 52% in group 1 
and 50% in group 2 (p = 0.537) ( table 2 ). These differ-
ences were not statistically significant ( fig. 1 ,  2 ).
 Complications 
 Of the entire cohort, 55.4% (139/251 patients) had at 
least one complication (CDC I–V). In groups 1 and 2, 
52.3% (104/199) and 67.3% had at least one complication 
(CDC I–V), respectively. CDC grade  ≥ III complications 
were noted in 23% (58/251) of patients: 24.1% (48/199) in 
group 1 and 19.2% (10/52) in group 2 ( table 2 ). We sub-
divided complications with CDC grade  ≥ III into early 
complications (0–30 days after RC), delayed complica-
tions (31–90 days after RC) and late complications (91–
365 days after RC). The majority of major complications 
(CDC grade  ≥ III) occurred in the first 30 days following 
RC, but there was no statistically significant difference 
between both groups. In multivariate logistic regression, 
of the clinical parameters assessed at time of diagnosis, 
only prior abdominal surgery influenced significantly 
CDC grade III–IV.
 Discussion 
 In the coming decades, demographic changes in 
Western countries will result in a further aging popula-
tion  [20] . The incidence of BC also increases with age and 
is 11-fold higher in patients ≥65 years compared to pa-
tients <65 years. In addition, elderly patients (≥65 years) 
have a 16-fold higher BC mortality rate compared to pa-
tients <65 years, and this increases with advanced age 
 [20–22] . Age also represents a strong and independent 
risk factor for the presence of BC, as the peak age for BC 
is advancing and now estimated at 85 years  [20, 22] . El-
derly patients with increased comorbidities, decreased 
physiologic reserve and advanced tumor stage present 
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a therapeutic dilemma  [14] . Although RC remains the 
gold standard for the treatment of muscle-invasive BC 
 [7] , analyses of SEER data show that only 12% of octoge-
narians with invasive BC undergo radical surgery. This 
is presumably due to the concerns of increased morbid-
ity and mortality with surgery in the elderly population 
which can easily outweigh the benefit of surgical extirpa-
tion  [23] .
 Contemporary mortality and morbidity rates of pa-
tients undergoing RC are lower than in previous decades 
 [24, 25] . Prior to 1990, the perioperative mortality in 
large series (>100 subjects) ranged from 2.4 to 15%. Over 
the past decade, these rates have been reduced to approx-
imately 0–3.9%  [25] . Little is known however about mor-
tality and morbidity rates in the elderly population treat-
ed with RC. Although it is reported that RC in the el derly 
population provides similar disease control and survival 
outcomes as it does in younger cohorts  [9, 23] , large se-
ries of patients are not available. An age over 70 years has 
been suggested to be a risk factor for higher complication 
rates  [14, 25–28] , although it seems proper patient selec-
tion here is more important than chronological age alone 
 [27] .
 The CDC is the most commonly used system to define 
and grade postsurgical complications  [19] . In our study, 
overall 139 patients (55.4%) suffered a CDC (I–IV) com-
plication. This is comparable with results reporting mor-
bidity rates of patients undergoing RC in the range of 29–
61%  [8, 23] . In group 2 (>85 years old) the rate of CDC 
grade II complications was two times higher as than in 
group 1. However, >33.3% in group 2 had blood transfu-
sions for anemia prior to surgery, compared to 20% in 
group 1.
 Concentrating on major complications (CDC grade 
 ≥ III) there was no significant difference between group 1 
(24.1%) and group 2 (19.2%). However, group 2 had sig-
nificantly less patients (52 vs. 199) and this lack of differ-
ence could reflect a selection bias.
 A significant difference was seen in the 90- day mortal-
ity rate between patients aged  ≥ 75–84 and  ≥ 85 years. The 
90-day mortality rate in group 2 increased 5-fold in com-
parison to the 30-day mortality rate in this group of pa-
tients. In multivariate logistic regression, of the clinical 
parameters assessed at time of diagnosis, only prior ab-
dominal surgery influenced significantly CDC grade III–
IV. Careful follow-up surveillance is therefore recom-
mended in the first 90 days after RC. This has also been 
noted by Donat et al.  [23] and Tyritzis et al.  [13] . The 
average time of hospitalization between American and 
European patients was as follows: the European time of 
hospitalization was between 10 and 90 days (mean 24, 
median 21) and the American one was between 2 and 51 
days (mean 11, median 9 days). Interestingly, the 90-day 
mortality in the American group is 12% compared to 
8.4% in the European group, the difference is not statisti-
cally significant.
 According to the 90-day mortality, overall 15 patients 
(7.5%) died in group 1: 4 patients died of a surgically re-
lated complication, 4 of reasons not related to BC, 4 for 
an acute cardiac event, and 3 from a respiratory event. In 
group 2, 6 patients died of a surgically related complica-
tion; 1 following esophageal surgery in another division, 
1 due to aspiration pneumonia, and 2 of unknown rea-
sons. In group 1, the surgically related deaths were re-
lated to sepsis in all 4 patients. In group 2, death resulted 
from sepsis in 3 patients, eventration in 1, intestinal anas-
tomotic leak in 1, and rectal perforation with peritonitis 
in 1 patient. There are several limitations in our study. 
All cases were performed in high-volume centers, but in 
four different countries on two continents, which may be 
problematic and this may not reflect other institutional 
results. Proper patient selection, surgery in a high-vol-
ume center, experienced nursing care and excellent peri-
operative management may contribute to the prevention 
of morbidity and mortality  [11] . In addition, in all insti-
tutions, some patients were not offered RC, suggesting 
that these elderly patients are carefully selected. Interest-
ingly, there was no significant difference in the morbid-
ity and mortality rate between the US and European cen-
ters suggesting similar selection criteria, surgical treat-
ment and postoperative care. Despite this, the 90-day 
mortality rates for all patients aged  ≥ 75 years are not sig-
nificant but a trend and more research is necessary to 
define who best would benefit from cystectomy or alter-
native therapy. Adopting a 90-day morbidity and mor-
tality definition might deliver a more realistic picture of 
the risks of RC. Further studies are necessary to evaluate 
this aspect.
 Conclusion 
 We sought to analyze a large series of elderly patients 
to describe outcomes after RC. Our experience suggest 
that RC can be safe and effective in properly selected old-
est-old patients (>84 years) with a high 90-day mortality 
rate, but no significant difference in overall survival be-
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